APA 6th Edition Kuzman, I. (2018). Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija. Medicus, 27 (2 Sumamed), 127-133. Preuzeto s https://hrcak.srce.hr/214604
MLA 8th Edition Kuzman, Ilija. "Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija." Medicus, vol. 27, br. 2 Sumamed, 2018, str. 127-133. https://hrcak.srce.hr/214604. Citirano 06.12.2019.
Chicago 17th Edition Kuzman, Ilija. "Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija." Medicus 27, br. 2 Sumamed (2018): 127-133. https://hrcak.srce.hr/214604
Harvard Kuzman, I. (2018). 'Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija', Medicus, 27(2 Sumamed), str. 127-133. Preuzeto s: https://hrcak.srce.hr/214604 (Datum pristupa: 06.12.2019.)
Vancouver Kuzman I. Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija. Medicus [Internet]. 2018 [pristupljeno 06.12.2019.];27(2 Sumamed):127-133. Dostupno na: https://hrcak.srce.hr/214604
IEEE I. Kuzman, "Azitromicin: i nadalje nezaobilazan antibiotik u lijecenju respiratornih infekcija", Medicus, vol.27, br. 2 Sumamed, str. 127-133, 2018. [Online]. Dostupno na: https://hrcak.srce.hr/214604. [Citirano: 06.12.2019.]
Sažetak For over twenty years, due to its unique pharmacokinetic profile, i. e. clinical efficacy, simple dosing and good tolerability, azithromycin was the preferred antibiotic, especially for the treatment of acute respiratory infections. As a result of an increasing trend in pneumococcal resistance to penicillin and macrolides, azithromycin has lost this prime position, but it still remains an important and indispensable antibiotic. Due to the inefficacy of beta-lactam antibiotics, azithromycin remained the first-line antibiotic for the treatment of atypical pneumonia and pertussis. Furthermore, combined with beta-lactam antibiotics, it plays a major role in the treatment of severe cases of pneumonia. Azithromycin is an alternative choice for the treatment of upper respiratory tract infections (pharyngitis, sinusitis, and otitis media) and acute COPD exacerbations in patients allergic to beta-lactam antibiotics. New discoveries regarding immunomodulatory and anti-inflammatory effect of macrolides have led to the use of azithromycin in patients with cystic fibrosis and other chronic respiratory diseases.